ConductScience.org, home

Paper22909192

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.

Klyuchnikov E and 10 others. Br J Haematol, 2012. Cited by 47 papers, by iCite.

Cite this record

ConductScience Library. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Papers, record 22909192. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22909192

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.
PubMed
Journal
Br J Haematol
PubMed
Year
2012
PubMed
Publication types
Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
47
iCite
Relative citation ratio, by iCite
1.36
iCite
Revised in PubMed
2020-12-22
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Klyuchnikov EEvgeny
2Holler EErnst
3Bornhäuser MMartin
4Kobbe GGuido
5Nagler AArnon
6Shimoni AAvichai
7Könecke CChristian
8Wolschke CChristine
9Bacher UUlrike
10Zander ARAxel R
11Kröger NNicolaus

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hematopoietic Stem Cell TransplantationMajor topic
Living DonorsMajor topic
Lymphocyte TransfusionMajor topic
Primary MyelofibrosisMajor topic
Acute Disease
Adult
Aged
Disease-Free Survival
Female
Follow-Up Studies
Graft vs Host Disease
Humans
Male
Middle Aged
Salvage Therapy
Survival Rate
Transplantation, Homologous

Source PubMed

Download CSV of topics

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.

PMIDTitleJournalYearIn PapersSource
42776827Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: Evolving Indications, Conditioning Strategies, and Outcomes.Hematol Rep2026https://conductscience.org/library/papers/42776827PubMed
40119918Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.Ann Hematol2025https://conductscience.org/library/papers/40119918PubMed
40079242Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.Am J Hematol2025https://conductscience.org/library/papers/40079242PubMed
38321269Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation.Bone Marrow Transplant2024https://conductscience.org/library/papers/38321269PubMed
37404772Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation.Hemasphere2023https://conductscience.org/library/papers/37404772PubMed
37365186Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation.Blood Cancer J2023https://conductscience.org/library/papers/37365186PubMed
36959692Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single CenterBalkan Med J2023https://conductscience.org/library/papers/36959692PubMed
36940410Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation.Blood2023https://conductscience.org/library/papers/36940410PubMed
35419771Improving allogeneic stem cell transplantation in myelofibrosis.Int J Hematol2022https://conductscience.org/library/papers/35419771PubMed
35051996Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis.Blood Adv2022https://conductscience.org/library/papers/35051996PubMed
34040148
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.
Leukemia2021https://conductscience.org/library/papers/34040148PubMed
34017327Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021.Front Immunol2021https://conductscience.org/library/papers/34017327PubMed
33824436Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT.Bone Marrow Transplant2021https://conductscience.org/library/papers/33824436PubMed
33718228Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.Front Oncol2021https://conductscience.org/library/papers/33718228PubMed
33114179Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis.Cancers (Basel)2020https://conductscience.org/library/papers/33114179PubMed
32806517Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms.Cancers (Basel)2020https://conductscience.org/library/papers/32806517PubMed
32110286Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.Ther Adv Hematol2020https://conductscience.org/library/papers/32110286PubMed
31296578Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.Haematologica2021https://conductscience.org/library/papers/31296578PubMed
28714945Impact of molecular residual disease post allografting in myelofibrosis patients.Bone Marrow Transplant2017https://conductscience.org/library/papers/28714945PubMed
28499938Allogeneic Stem Cell Transplantation in Myelofibrosis.Biol Blood Marrow Transplant2017https://conductscience.org/library/papers/28499938PubMed

See all 28 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22909192

GET https://conductscience.org/api/papers/v1/22909192/cited_by?page=2